Our Take
Keytruda's phase II head-neck result clears a long-blocked path (six prior ICI combos failed), but the p-value (0.09) sits on the margin; phase III will settle whether this works outside the trial. The endometrial ADC data is real, but Gilead's competing asset is still in play and may narrow Merck's first-mover edge.
Why it matters
Merck faces Keytruda's imminent patent cliff and needs validated assets to fill the gap. These readouts, especially the non-surgical HNSCC opportunity (40% of locally advanced cases currently uncovered), show the company is building a post-Keytruda oncology franchise. Oncology payers and CROs track these phase III transitions closely; positive phase II readouts that miss statistical significance thresholds still influence clinical practice but require confirmation before reimbursement pressure shifts.
Do this week
Oncology medical directors: audit your current head-neck squamous cell carcinoma protocols to flag p16-positive oropharyngeal patients managed non-surgically; cross-check NCCN guideline restrictions versus KEYCHAIN eligibility before phase III opens, so you can pre-plan trial enrollment and patient counseling.
Phase II Pembrolizumab-Radiotherapy Clears Six Failed Predecessors in Head-Neck Cancer
The University of California San Diego, in partnership with Merck, presented phase II data from the KEYCHAIN trial (NCT03383094) at ASCO 2026. The study enrolled 102 patients with unresected, unfavorable-risk p16-positive head and neck squamous cell carcinoma (HNSCC) and compared concurrent and adjuvant pembrolizumab plus radiotherapy against cisplatin plus radiotherapy, the current standard of care.
Keytruda achieved a two-year progression-free survival (PFS) rate of 84% (95% CI: 74–96%) versus 70% (95% CI: 58–85%) for cisplatin (hazard ratio 0.58, one-sided p = 0.09). Overall survival at two years favored pembrolizumab even more: 98% (95% CI: 94–100%) versus 85% (95% CI: 76–96%) for standard care (hazard ratio 0.34, two-sided p = 0.11). Grade 3 or higher treatment-related adverse events occurred in 36% of the pembrolizumab arm versus 46% with cisplatin (per the company presentation).
This result is historically significant: six prior phase III trials—JAVELIN HN100, GORTEC REACH, PembroRad, KEYNOTE-412, NRG HN004, and IMvoke010—all failed to meet their primary endpoints when adding immune checkpoint inhibitors to chemoradiotherapy in locally advanced HNSCC. KEYCHAIN's positive readout stands as the first successful phase II signal in this combination space in years.
Merck already holds FDA approval for pembrolizumab in locally advanced HNSCC with PD-L1 combined positive score ≥1 as neoadjuvant monotherapy followed by adjuvant chemoradiotherapy. However, NCCN guidelines restrict use to resectable disease and explicitly exclude p16-positive oropharyngeal cases. This restriction leaves approximately 40% of the locally advanced HNSCC population (those managed surgically) without approved ICI options (per GlobalData epidemiology data). Over 63,000 locally advanced HNSCC cases were diagnosed across six major markets in 2024 alone.
Sacituzumab Tirumotecan Validates Merck's TROP2 ADC Platform and Endometrial Strategy
Merck announced positive interim results from the TroFuse-005 phase III trial of sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate, versus physician's choice chemotherapy in patients with advanced or recurrent endometrial cancer who had progressed on platinum-based therapy and anti-PD-1/PD-L1 treatment. The trial met both primary endpoints: overall survival and progression-free survival, plus the key secondary endpoint of objective response rate (per company announcement).
The competitive landscape matters here. Gilead's Trodelvy (sacituzumab govitecan), another TROP2-directed ADC, is being evaluated in ASCENT-GYN-01 in a nearly identical patient population. Merck now appears ahead on timing: the first positive global phase III readout in the post-platinum, post-anti-PD-1/PD-L1 setting. If Merck files quickly, it could secure regulatory approval before Gilead's trial readout matures, narrowing Gilead's path to market entry.
Commercially, this readout supports Merck's broader post-Keytruda strategy. Endometrial cancer is a space where Keytruda has already moved into first-line treatment. Sacituzumab tirumotecan would complete a treatment continuum: Keytruda-based therapy earlier, sac-TMT positioned after platinum and immunotherapy resistance. Analyst estimates project global sales for sac-TMT at $2.2 billion by 2030 versus $2.4 billion for Trodelvy (per GlobalData consensus forecast).
Merck has also secured a Commissioner's National Priority Voucher for sac-TMT, which can substantially shorten FDA review timelines once the company files. The TROP2 ADC is in 22 ongoing phase III trials across multiple tumor types (per GlobalData clinical trial database), suggesting Merck is building a platform, not a one-shot asset.
What Oncologists and Payers Should Track
The KEYCHAIN phase II result carries a statistical caveat: the one-sided p-value of 0.09 sits at the margin of conventional significance thresholds. Phase III results will be definitive. Clinical teams managing non-surgically treated p16-positive oropharyngeal cancer should monitor the phase III enrollment timeline; this population has lacked validated ICI options for years.
For endometrial cancer, payers should expect rapid regulatory filings from Merck once the company accumulates mature overall survival data. The safety profile (manageable hematologic and GI toxicity) and OS advantage will be the decisive factors for reimbursement formularies. If sac-TMT delivers a clear survival benefit over physician's choice chemotherapy, it will likely become the new standard post-platinum and post-immunotherapy.
Both readouts underscore Merck's reliance on pipeline validation to offset Keytruda's approaching loss of exclusivity. The endometrial ADC data is particularly important because it extends the company's platform beyond PD-1 monotherapy and combination regimens.